Private M&A 2024: Key Trends and Forecasts
What Goes On Inside Your Boardroom? Investors Want To Know
Public M&A Day in Frankfurt
Global Dealmaking in 2013: Why the Best Strategies will Dominate
As the page turned on 2025, optimism was high among life sciences dealmakers. Elections in the U.S. and other major economies had concluded, interest rates were poised to come in to focus, and the regulatory environment...more
During this session, the panelists discussed notable developments within the life sciences industry with a specific focus on the GLP-1 drug market and its opportunities for improvement in patient satisfaction and dosage. They...more
European biotech just enjoyed its most abundant quarter in nearly two years in a tentative sign of a renaissance in the sector. There were 46 deals in Q1 2023, the second biggest year for deals in the region on Mergermarket...more
After a year of historic profits in 2021 following the mass roll-out of COVID-19 vaccines and related treatments, big pharma companies armed with cash for deals have been shifting their attention - Overall, pharma, medical...more
Dealmaking in the pharma, medical and biotech (PMB) subsectors was driven by both old and new market trends in 2022 - Following a ground-breaking year for dealmaking in 2021, global healthcare M&A remained robust in 2022,...more
The value of healthcare M&A in H1 surpassed pre-pandemic levels - Healthcare M&A (including pharma, biotech and medical) saw strong growth over the first half of 2021 as investors continued to pursue deal opportunities in...more
Dealmaking within the PMB sector enjoyed an impressive start as companies across the globe embarked on their post-pandemic recovery - The global pharma, medical and biotech (PMB) sector saw US$95.4 billion in deal...more
FDI restrictions have been on the political agenda in Europe and further afield for at least the past year, and following the outbreak of COVID-19 and the changed economic landscape, the approach in jurisdictions across the...more